Peptide Comparison
Relaxin-2 (Serelaxin)vsBPC-157
Recombinant human relaxin-2 studied for acute heart failure recovery and cardiovascular support
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
Relaxin-2 (Serelaxin)
1–10 mcg
BPC-157
250–500 mcg
Frequency
Relaxin-2 (Serelaxin)
Once daily
BPC-157
Once daily
Administration
Relaxin-2 (Serelaxin)
Intravenous (IV) infusion
BPC-157
Subcutaneous injection
Cycle Length
Relaxin-2 (Serelaxin)
8-12 weeks
BPC-157
4-6 weeks
Onset Speed
Relaxin-2 (Serelaxin)
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
Relaxin-2 (Serelaxin)
Limited human trials
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Cardiovascular Function
Heart Failure Support
Acute Medical Management
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
Relaxin-2 (Serelaxin)
Molecular Formula
C256H408N74O74S8
Molecular Weight
5,963 Da (Daltons)
Half-Life
Varies by route of administration
Bioavailability
Varies by route of administration
CAS Number
See PubChem for identifiers
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
Relaxin-2 (Serelaxin)
BPC-157
Applications
Best
suited for
Relaxin-2 (Serelaxin)
Acute heart failure symptom management
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on acute heart failure symptom management. Research supports its use in this area.
Cardiovascular recovery and support
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on cardiovascular recovery and support. Research supports its use in this area.
Hospital-based therapeutic interventions
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on hospital-based therapeutic interventions. Research supports its use in this area.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
Relaxin-2 (Serelaxin)
Common
- Hypotension (low blood pressure) - most common
- Tachycardia (increased heart rate)
- Headache
- Nausea
- Dizziness
- Peripheral edema (swelling)
- Increased creatinine levels
- Hyperkalemia (high potassium)
- Syncope (fainting)
- Atrial fibrillation
- Blood pressure checks every 2-4 hours during infusion
- Kidney function (creatinine and eGFR)
- Electrolytes, particularly potassium
- Heart rate and cardiac rhythm
- Urine output
Serious
- Severe cardiovascular events
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
Relaxin-2 (Serelaxin)
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Serelaxin (recombinant relaxin-2) completed Phase III heart failure trials with favorable safety profile and cardiovascular benefit signals. Hypotension occurs in 20-25% of subjects requiring hemodynamic monitoring; no serious adverse events directly attributable to serelaxin beyond expected vasodilatory effects. Flushing and headaches mild and transient. No serious immunogenicity despite being recombinant human peptide; repeat dosing shows consistent response.
Contraindications
- xSevere hypotension or hemodynamic instability
- xPregnancy (despite relaxin's natural role)
- xAcute kidney injury or severe renal dysfunction
- xRecent myocardial infarction (within 7 days)
- xUncontrolled arrhythmias
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose Relaxin-2 (Serelaxin) if...
- Acute heart failure symptom management
- Cardiovascular recovery and support
- Hospital-based therapeutic interventions
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health